| Market Capitalization (Millions $) |
191 |
| Shares
Outstanding (Millions) |
61 |
| Employees |
141 |
| Revenues (TTM) (Millions $) |
34 |
| Net Income (TTM) (Millions $) |
-108 |
| Cash Flow (TTM) (Millions $) |
-32 |
| Capital Exp. (TTM) (Millions $) |
2 |
Business Description
Voyager Therapeutics Inc is a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases. The company aims to use gene therapy to deliver potentially transformative treatments directly to the affected areas of the brain. Voyager Therapeutics is developing therapies for diseases such as Parkinson's disease, Huntington's disease, and Amyotrophic Lateral Sclerosis (ALS). The company's approach involves using adeno-associated virus (AAV) vectors to deliver therapeutic genes to specific brain regions. Voyager Therapeutics is conducting clinical trials to evaluate the safety and efficacy of its gene therapies, with the goal of providing new treatment options for patients suffering from these devastating diseases.
Company Address: 75 Hayden Avenue Lexington 2421 MA
Company Phone Number: 259-5340 Stock Exchange / Ticker: NASDAQ VYGR
|
0.42% 
181.93 %